|Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study.|
|PMID: 11457466 Owner: NLM Status: MEDLINE|
|To evaluate the role of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in children with an estimated risk of vascular occlusion reported to range from 7% to 16%, we conducted a prospective study in infants and children with underlying cardiac disease. One hundred and twenty-five children (neonate - 16 years) were investigated. In 9 infants out of the 125 children vascular occlusion occurred, closely related to cardiac catheterisation and arterial or venous lines during major cardiac surgery. Six of the nine neonates and infants with (n=6) and without (n=3) prothrombotic risk factors showed evidence of a basically impaired fibrinolytic system. Five of the nine infants showed increased PAI-1 clearly correlated to the 4G/4G genotype of the plasminogen activator-1 promoter polymorphism along with elevated t-PA concentration before the first diagnostic cardiac catheterisation was performed. One infant presented with increased t-PA concentration only. Five of the six children with reduced fibrinolytic capacity had further prothrombotic risk factors. Conclusion: Data of this study indicate that neonates and infants with underlying cardiac disease and basically increased PAI-1 due to the 4G/4G variant of the PAI-1 promoter polymorphism along with elevated t-PA levels in combination with further prothrombotic risk factors are at high risk of developing early thromboembolism during cardiac catheterisation.|
|U Nowak-Göttl; S Kotthoff; E Hagemeyer; R Junker; H G Kehl; H Vielhaber; D Kececioglu|
Related Documents :
|15151586 - Infant bath seats, drowning and near-drowning.
9122076 - Treatment with bifonazole shampoo for scalp seborrhea in infants and young children.
20863156 - A new hemostatic agent--ankaferd blood stopper: management of gastrointestinal bleeding...
21087706 - Randomized, controlled trial of individualized heparin and protamine management in infa...
21147386 - Neuromotor outcomes in infants with bronchopulmonary dysplasia.
7062166 - Clostridia isolated from the feces of infants during the first year of life.
|Type: Comparative Study; Journal Article; Multicenter Study|
|Title: Thrombosis research Volume: 103 ISSN: 0049-3848 ISO Abbreviation: Thromb. Res. Publication Date: 2001 Jul|
|Created Date: 2001-07-17 Completed Date: 2001-12-04 Revised Date: 2008-11-21|
Medline Journal Info:
|Nlm Unique ID: 0326377 Medline TA: Thromb Res Country: United States|
|Languages: eng Pagination: 93-101 Citation Subset: IM|
|Pediatric Hematology and Oncology, University Hospital Münster, D-48149 Münster, Germany. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
3' Untranslated Regions
Catheterization, Central Venous / adverse effects
Catheters, Indwelling / adverse effects
Factor V / genetics
Genetic Predisposition to Disease
Germany / epidemiology
Heart Catheterization / adverse effects*
Heart Defects, Congenital / blood*, surgery
Lipoprotein(a) / genetics
Plasminogen Activator Inhibitor 1 / genetics, physiology*
Promoter Regions, Genetic / genetics
Protein C Deficiency / epidemiology, genetics
Prothrombin / genetics
Thromboembolism / epidemiology*, etiology
Thrombophilia / epidemiology*, genetics
Tissue Plasminogen Activator / physiology*
|0/3' Untranslated Regions; 0/Lipoprotein(a); 0/Plasminogen Activator Inhibitor 1; 0/factor V Leiden; 9001-24-5/Factor V; 9001-26-7/Prothrombin; EC 188.8.131.52/Tissue Plasminogen Activator|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antiplatelet and anticoagulant effects of "HN-11 500," a selective thromboxane receptor an...
Next Document: PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease.